Theravance Biopharma Inc. is forging ahead with a fresh plan to get an approval and partnership for ampreloxetine despite the drug candidate having failed two advanced studies in its original broad indication of orthostatic hypotension.
The firm hopes to expedite the norepinephrine reuptake inhibitor candidate as a treatment for people with multiple system atrophy (MSA) with neurogenic orthostatic hypotension (nOH) after this patient subgroup
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?